ABBVIE INC.

The company is a research-based pharmaceuticals business that is engaged in the discovery, development, manufacture, and sale of a line of pharmaceuticals and biologics worldwide. It was established in 2012 and conducts business activities from its registered office in North Chicago, Illinois, United States.The company's principal products are HUMIRA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, juvenile idiopathic arthritis, and Crohn's disease as well as ulcerative colitis, and axial spondyloarthritis; Kaletra used in the treatment of HIV infection; Lupron used for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia; Synagis, a syncytial virus prevention product used to protect infants from severe respiratory disease; AndroGel for the treatment of adult males who have low testosterone; sevoflurane, an anesthesia product; Zemplar for the prevention and treatment of secondary hyperparathyroidism associated with stage 3, 4, or 5 chronic kidney disease; Synthroid used for the treatment of hypothyroidism; Creon for the treatment of pancreatic exocrine insufficiency; and TriCor, Trilipix, Simcor, and Niaspan for the treatment of dyslipidemia. It also has a pipeline of new medicines consisting of approximately 20 compounds or indications in Phase II or Phase III development in medical specialties, such as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. In addition, the company offers other products, such as Duodopa, a levodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's disease. It sells its products directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers.